Reading Your PGT-A and PGT-M Results: What the Report Can and Cannot Tell You Before Transfer

The portal notification arrives on a Tuesday afternoon, between a work call and the school run. Seven embryos went for biopsy two weeks ago. The PDF opens to a grid of codes: two say euploid, three say aneuploid with chromosome numbers attached, one says mosaic, one says no result. Underneath each sits a grade like 4AA or 5BB. There is no sentence that says what to do next.

That gap between data and decision is where most of the anxiety lives. People want their pgt results explained in plain language, and they want to know which parts of the report matter for the transfer conversation and which parts are lab detail. Both questions are fair, and both have honest answers.

This explainer walks through what preimplantation genetic testing measures, what each label means, what the biopsy genuinely cannot see, and how the report fits alongside embryo grading, your age, and your history when your team talks you through the transfer plan.

What does PGT actually test, and how does the embryo biopsy work?

Preimplantation genetic testing (PGT) is a laboratory analysis of a few cells removed from an embryo created through in vitro fertilization (IVF), performed before any embryo is transferred to the uterus. It comes in three flavors, and the letters after the hyphen tell you which question the lab asked.

PGT-A screens for aneuploidy, meaning an embryo with extra or missing chromosomes. Humans normally carry 46 chromosomes arranged in 23 pairs, and aneuploidy is the most common reason embryos fail to implant or end in early miscarriage. PGT-M looks for a single monogenic condition, a disorder caused by a variant in one specific gene, such as cystic fibrosis or Huntington disease, that is already known to run in the family. PGT-SR checks for structural rearrangements when a parent carries a known translocation or inversion, a situation where pieces of chromosomes have swapped places or flipped.

The procedure itself happens around day five to seven of embryo development, when the embryo has become a blastocyst: a hollow ball with an inner cell mass that will become the fetus and an outer layer called the trophectoderm that will become the placenta. An embryologist uses a laser and a fine pipette to remove a handful of trophectoderm cells. The embryo is then frozen by vitrification, a rapid-freezing method, while the cells travel to a genetics laboratory. Results typically return within a couple of weeks, according to Cleveland Clinic, though the exact timing depends on the laboratory.

Two features of that description shape everything else in this article. First, the test samples the future placenta, not the future baby. Second, it samples only a few cells out of the hundred-plus that make up a blastocyst. The report is a strong, useful signal. It is not a photograph of the whole embryo.

PGT results explained: how to read PGT test results on a PGT-A report

Most PGT-A reports use four categories, and learning to read them is mostly a matter of knowing what the lab is confident about and what it is hedging.

Euploid means the sampled cells showed the expected number of copies for every chromosome tested. Some labs write this as “normal” or “no aneuploidy detected.” This is the category clinicians usually prioritize for transfer.

Aneuploid means at least one whole chromosome was present in the wrong number across the sampled cells. The report will usually specify which one, written as a plus or minus sign and a chromosome number, so “+21” means an extra copy of chromosome 21 (trisomy 21, the cause of Down syndrome) and “-X” means a missing X chromosome. Some reports list a segment rather than a whole chromosome, which indicates a partial gain or loss.

Mosaic means the sampled cells disagreed with each other: some appeared euploid, some aneuploid. This category gets its own section below because it is where interpretation becomes genuinely difficult.

No result, sometimes labeled “inconclusive” or “amplification failure,” means the laboratory could not obtain enough usable DNA from the biopsy to call the embryo either way. It says nothing about the embryo’s health.

Here is the distinction that matters most when you sit with the grid: euploid versus aneuploid is a statement about the trophectoderm cells that were sampled. It is a strong predictor of how the embryo is likely to behave, and Cleveland Clinic and Mayo Clinic both describe PGT-A as a tool to help choose which embryo to transfer, not as a guarantee about the pregnancy. The report ranks embryos. It does not promise an outcome for any of them, and it does not diagnose a future child.

Euploid vs aneuploid embryo: what the two most common labels do and do not settle

People often ask whether a euploid label means the embryo is healthy. The precise answer is narrower and more useful: it means the tested cells had the expected chromosome count for the chromosomes on the panel. Chromosome count is one dimension of health. It is a very important one, because whole-chromosome errors account for a large share of implantation failure and first-trimester loss, which is why fertility teams weight it heavily. But it is silent on single-gene conditions, on structural birth differences that arise during organ development, and on anything caused by the uterine environment.

An aneuploid label is treated differently by most guidelines and laboratories depending on what was found. Some aneuploidies, such as trisomy 21, 18, or 13, or sex chromosome differences, are compatible with a live birth and a life; most fertility teams still do not transfer them by default, and many laboratories flag them as not recommended for transfer. Other aneuploidies are not compatible with ongoing pregnancy at all. The chromosome number on the report is therefore worth asking about specifically rather than treating every aneuploid embryo as identical.

Two honest caveats belong here. Aneuploidy in the trophectoderm does not always mean aneuploidy in the inner cell mass, because errors can arise after fertilization and be unevenly distributed. And laboratories set their own thresholds for how much abnormal signal tips a sample from euploid into mosaic, or from mosaic into aneuploid. Two labs looking at the same embryo can, at the margins, give it different labels. Cleveland Clinic notes that PGT can produce false positives and false negatives for this reason, which is why the recommendation for prenatal testing during any resulting pregnancy does not go away.

PGT-A mosaic embryo results: why the gray zone exists

A mosaic result is the one that most often sends people back to the search bar at midnight. The word means the embryo, or at least the sample, contains two or more cell lines with different chromosome make-ups. That can happen when a chromosome division error occurs after fertilization, so some daughter cells inherit the error and others do not.

Reports usually describe mosaicism with a percentage of abnormal signal, a chromosome number, and sometimes the words “low-level” or “high-level.” The percentage is the laboratory’s estimate of what fraction of the sampled cells carried the error, and cut-offs vary between labs. Be cautious about treating those numbers as precise. They are inferred from a mixed DNA signal in a few cells, not counted cell by cell.

Three things are known with reasonable confidence, and three things are not.

• Known: mosaic embryos can and do result in healthy births, which is why professional bodies no longer recommend automatically discarding them.
• Known: euploid embryos are generally prioritized ahead of mosaic embryos when both are available.
• Known: the type of mosaicism matters; whole-chromosome versus segmental, and which chromosome is involved, changes how clinicians weigh it.
• Not known: whether a given mosaic result in the trophectoderm reflects the inner cell mass at all. The biopsy might have caught the only abnormal cells, or missed most of them.
• Not known: a reliable way to predict, embryo by embryo, which mosaics will self-correct, which is a proposed mechanism that remains incompletely understood.
• Not known: a universal threshold that separates “transferable” from “not transferable.”

Because of that uncertainty, a mosaic result is a conversation, not a verdict. Genetic counseling is the setting where that conversation belongs, and Cleveland Clinic and MedlinePlus both describe counseling before and after genetic testing as standard rather than optional.

PGT-M results explained: affected, unaffected, carrier, and why a set-up phase comes first

A PGT-M report looks different from a PGT-A report because it answers a different question. Instead of counting chromosomes, the lab is looking for one particular gene variant that has already been identified in a parent or previous child.

Before any embryos are tested, the laboratory usually runs a preparatory phase, sometimes called probe design or work-up, using DNA from the intended parents and often from other relatives. The purpose is to build a family-specific test. Most labs do not rely on detecting the variant directly in a few cells alone; they also track nearby genetic markers that are inherited alongside the variant, a technique called linkage analysis. This set-up can take weeks to months, according to Cleveland Clinic, and it happens before the IVF cycle rather than after the biopsy.

The results then fall into a small number of categories that depend on how the condition is inherited. For an autosomal recessive condition, where a child is affected only when both copies of the gene carry a variant, embryos may be reported as unaffected (no variant), carrier (one copy, typically no symptoms), or affected (two copies). For an autosomal dominant condition, where one variant is enough, the report typically reads unaffected or affected. For X-linked conditions, the sex chromosomes matter, and the report may combine the variant result with chromosome findings.

Many people undergoing PGT-M also have PGT-A run on the same biopsy, and the report will then show both results side by side. An embryo can be unaffected for the family condition and aneuploid, or a carrier and euploid. Which combination is prioritized for transfer is a decision for you and your team, and carrier embryos are, in most guidelines, considered acceptable for transfer because carriers are generally healthy.

Is 4AA or 5AA better? Embryo grading versus the genetic result

The grade printed next to the genetic result describes what the embryo looked like under the microscope on the day of biopsy. It is a morphology score, not a genetic finding, and the two are often confused.

Most laboratories use a version of the Gardner system. The number, usually 1 to 6, describes how expanded the blastocyst is and whether it has begun to hatch out of its outer shell, the zona pellucida. A 4 is fully expanded; a 5 has started hatching; a 6 has hatched completely. The first letter grades the inner cell mass and the second grades the trophectoderm, each from A (many tightly packed cells) to C (few cells or a loose appearance).

So is 4AA or 5AA better? Both describe a well-developed embryo with high-quality cell layers. The difference between 4 and 5 is mostly about timing of expansion and hatching, which can be influenced by when the biopsy happened and by the laser opening created for it. Embryologists generally do not treat a 4AA and a 5AA as meaningfully different in quality. The letters carry more weight than the number at that stage, and a 4AA would typically be considered ahead of a 5BC.

The more useful mental model is that grading and genetics answer separate questions. Grading tells you how the embryo developed to day five or six; PGT-A tells you about its chromosomes. A euploid 3BB embryo has a chromosome result in its favor that a beautiful-looking untested embryo does not. Conversely, an aneuploid 5AA is still aneuploid. When a report offers two euploid embryos of different grades, teams often use grade as the tiebreaker, but that ordering is a clinical judgment for your embryologist and physician, not a rule you need to apply yourself.

What percentage of embryos are PGT normal, and why your age changes the answer

This is one of the most searched questions about PGT, and the honest answer is that there is no single percentage. The proportion of euploid embryos depends most strongly on the age of the person who provided the eggs, and it falls steadily from the early thirties onward.

The mechanism is not mysterious. Eggs are formed before birth and sit in an arrested state for decades. When an egg finally completes its chromosome divisions around ovulation, the machinery that separates chromosome pairs is more error-prone in older eggs, so a larger share of resulting embryos end up with an extra or missing chromosome. Mayo Clinic and the CDC both describe maternal age as the strongest predictor of IVF outcomes for this reason. Sperm contribute to aneuploidy far less often, though they are not irrelevant.

Because the proportion varies so much between individuals, be wary of any single figure quoted as “the” euploid rate. Two people the same age can have very different results in the same cycle. Egg quantity also matters separately from quality: a cycle that yields many blastocysts has more chances of including a euploid one, even if the percentage is low.

What this means for reading your own report is straightforward. A grid with more aneuploid than euploid embryos is a common pattern, especially after the mid-thirties, and it is not a sign that the cycle went wrong or that the lab made errors. It reflects biology that PGT-A was designed to reveal before transfer rather than after implantation failure or miscarriage. Your team can put your ratio in the context of your age group and your prior cycles, which is more informative than any national average.

Can a PGT normal embryo have Down syndrome? What the report cannot rule out

Down syndrome is caused by an extra copy of chromosome 21, and detecting whole-chromosome gains like trisomy 21 is exactly what PGT-A is designed to do. In the great majority of cases, an embryo reported as euploid will not have trisomy 21. But “very unlikely” is not the same as “impossible,” and understanding why is the clearest way to understand the test’s limits.

The first reason is sampling. The biopsy takes trophectoderm cells, and if the embryo is mosaic with the abnormal cells concentrated in the inner cell mass, the sample can miss them. The second reason is technical: every laboratory method has a small false-negative rate, which Cleveland Clinic explicitly notes for PGT. The third reason is that a few individuals with Down syndrome have a form caused by a translocation or by mosaicism arising later, which can present differently from a simple whole-chromosome count; MedlinePlus describes these variants of the condition.

The same logic applies more broadly. A euploid label does not screen for:

• Single-gene disorders, unless PGT-M was specifically set up for a known family variant.
• Very small deletions or duplications below the resolution of the platform used.
• Structural birth differences such as heart or neural tube variations that arise during organogenesis.
• Conditions influenced by the pregnancy environment, including some effects of maternal health conditions or exposures.
• New, spontaneous variants that arise after the biopsy.

This is why every major source, including Cleveland Clinic and NHS guidance on IVF, treats PGT as a pre-transfer selection tool and still recommends routine prenatal screening and, where indicated, diagnostic testing such as chorionic villus sampling or amniocentesis during a resulting pregnancy. A euploid result lowers the probability of a chromosomal condition substantially. It does not replace pregnancy care.

Who is PGT usually for, and who is usually asked to wait or to skip it

PGT is not a default step in IVF, and the groups for whom guidelines describe a clear rationale differ between the three test types.

PGT-M and PGT-SR have the most settled indications. They are offered to people who carry a known variant for a serious single-gene condition, or a known structural chromosome rearrangement, and who want to reduce the chance of passing it on. NHS guidance describes this use, historically called preimplantation genetic diagnosis, for couples with a specific inherited condition in the family. The set-up work described earlier means these tests are planned before egg retrieval, not added afterward.

PGT-A is more debated. It is most often discussed for people of advanced reproductive age, those with recurrent pregnancy loss, repeated implantation failure after transferring good-looking embryos, or a partner with severe male-factor infertility. Cleveland Clinic and Mayo Clinic present it as an option in these situations rather than a universal recommendation. For younger people with a good prognosis and few embryos, some teams advise against it because the chance of a euploid result is already high, the biopsy adds a small risk, and a “no result” or borderline mosaic call can complicate decisions about an embryo that might otherwise have been transferred.

People are usually asked to wait when a genetic work-up for PGT-M is incomplete, when a parental karyotype has not yet been obtained to clarify whether PGT-SR is the right test, or when the family variant has not been formally confirmed in a clinical laboratory. Waiting in these cases is not a delay for its own sake. It prevents building a test around the wrong target.

Whether PGT of any kind is appropriate for you is a shared decision with your fertility physician and a genetic counselor, weighing your age, embryo numbers, history, and values.

PGT-A, PGT-M, PGT-SR and prenatal testing compared

Because these tests are often discussed in the same appointment, a side-by-side view helps clarify which question each one answers and which it leaves open.

Test	What it looks for	When it happens	What it cannot tell you
PGT-A	Extra or missing chromosomes, whole or segmental, in biopsied trophectoderm cells	Day 5-7 embryo, before transfer	Single-gene disorders, small variants, structural birth differences, whether the inner cell mass matches the sample
PGT-M	One specific gene variant already identified in the family, tracked with linked markers	Day 5-7 embryo, after a preparatory work-up	Any condition other than the one tested for; chromosome number unless PGT-A is added
PGT-SR	Unbalanced products of a known parental translocation or inversion	Day 5-7 embryo, after parental karyotype	Usually cannot distinguish a balanced carrier embryo from a fully typical one
Prenatal screening (cell-free DNA, ultrasound)	Probability of common trisomies; structural findings on scan	During pregnancy	Screening only; a high-probability result needs diagnostic confirmation
Prenatal diagnosis (CVS, amniocentesis)	Chromosome and, if requested, gene analysis of placental or fetal cells	During pregnancy	Conditions not covered by the panel ordered; carries a small procedure-related risk

The pattern in the right-hand column is the point of the table. Each test is precise about one thing and silent about the rest. Pre-transfer testing improves the odds of choosing an embryo with the expected chromosome count or without a known family variant. Prenatal testing then checks the actual pregnancy, which is a different biological entity from a handful of placental cells frozen weeks or months earlier. MedlinePlus describes preimplantation and prenatal testing as complementary rather than interchangeable, and that framing is the one most fertility and obstetric teams use.

What are the risks of embryo biopsy, and what does "no result" really mean?

Any procedure that removes cells from an embryo carries some risk, and it is fair to want that risk described honestly rather than waved away.

The main risk is to the embryo itself. Trophectoderm biopsy, performed by an experienced embryologist, is generally considered to have a low impact on the embryo’s ability to develop, and Cleveland Clinic describes the removal of a few cells as usually not harmful. The word “usually” is doing real work. A small proportion of embryos do not survive biopsy and freezing, and a further small proportion do not survive thawing before transfer. Laboratories track these rates internally, and you are entitled to ask your clinic how often this happens in their hands.

The second risk is misclassification. Because the sample is small and the trophectoderm may not perfectly represent the inner cell mass, an embryo can be labeled aneuploid when the fetal cell line is actually euploid, or vice versa. Discarding a mislabeled embryo is a loss that cannot be undone, which is one reason many programs now store rather than discard mosaic embryos and revisit the decision later.

A “no result” is not a risk in the same sense, but it is a real outcome. It means too little DNA was recovered or the signal was too poor to interpret. It says nothing negative about the embryo’s chromosomes. Options your team may raise include re-biopsy, which means thawing, sampling again, and refreezing, with the attendant survival risks; transferring the embryo untested, treating it as an unknown; or holding it in storage while euploid embryos are used first. None of these is inherently correct. The choice depends on how many other embryos you have, your age, and your own view of uncertainty.

What the days and weeks after PGT results usually look like

Receiving the report is a milestone, but it is rarely the end of the timeline. What follows is fairly predictable in shape, even if the exact intervals vary between programs.

In the first few days, most clinics schedule a results consultation. This may be with your physician, a genetic counselor, or both. Expect to walk through each embryo, its genetic result, its grade, and any laboratory notes. If a mosaic or unexpected finding appears, this is when a counselor helps you weigh it. MedlinePlus describes post-test genetic counseling as a standard part of genetic testing for exactly this reason.

Over the following weeks, if a transfer is planned, the focus shifts to preparing the uterine lining. A frozen embryo transfer cycle typically involves either tracking a natural ovulation or using hormonal medication to build the lining, followed by a scheduled thaw and transfer. Medication in this phase works by mimicking the estrogen and progesterone signals that ordinarily prepare the endometrium; the specific protocol, its timing, and any changes are decisions for your prescribing clinician. Mayo Clinic describes this preparation phase as part of the overall IVF pathway.

The transfer itself is usually a brief outpatient procedure, and a pregnancy blood test typically follows roughly two weeks later, according to NHS guidance on IVF. If the test is positive, an early ultrasound is generally arranged in the following weeks, and prenatal care begins, including the routine screening described earlier.

If no euploid or transferable embryo was identified, the weeks after results look different: they involve a review of the cycle, a discussion of whether another retrieval is reasonable, and time. That last item is easy to underrate. Many people find the results conversation harder than the retrieval, and asking for a follow-up appointment rather than deciding on the spot is entirely reasonable.

What people often get wrong about PGT results

Because PGT reports look so definitive, a set of understandable misreadings has grown up around them. Correcting them changes how the grid feels.

“Euploid means the baby will be healthy.” Euploid means the sampled cells had the expected chromosome count. It says nothing about single-gene conditions not tested for, about structural development, or about the pregnancy itself. Prenatal care is still recommended.

“Aneuploid means the embryo is dead or defective.” Aneuploid embryos are often developing normally at the blastocyst stage, which is why they cannot be identified by appearance. Most are unlikely to implant or continue, but the label describes chromosomes, not viability in a crude sense.

“Mosaic means half the cells are abnormal.” The percentage on a report is an estimate from a mixed signal in a few cells. It is not a head count, and it may not reflect the inner cell mass at all.

“PGT-A guarantees a pregnancy.” It selects against a major cause of failure. It does not address uterine factors, lining receptivity, or the small proportion of euploid embryos that still do not implant. Cleveland Clinic and Mayo Clinic are both explicit that PGT does not guarantee a live birth.

“A higher grade means a better genetic result.” Grade and genetics are independent. A 5AA can be aneuploid; a 3BB can be euploid.

“PGT-A tests for everything.” It counts chromosomes. PGT-M must be built separately for each family variant, and neither test detects the majority of birth differences, which are not chromosomal in origin.

“Two labs would give the same result.” Thresholds for mosaicism and reporting conventions differ. The biology is the same; the label at the margins may not be.

The opinion worth holding onto is that PGT is most valuable as a way to order embryos for transfer and to avoid some predictable losses. Treated as a prophecy, it disappoints. Treated as a ranking tool with known blind spots, it does what it was designed to do.

Questions to ask your care team before transfer

The results consultation goes better when you arrive with specific questions rather than a general sense of worry. These are the ones that tend to change decisions, grouped by topic.

About the report itself:

• Which chromosomes are affected in each aneuploid embryo, and are any of them ones you would consider under any circumstances?
• For mosaic embryos, is the finding whole-chromosome or segmental, and what threshold does the laboratory use to call mosaicism?
• What platform was used, and what is its resolution for small gains and losses?
• For PGT-M, did the linked markers agree with the direct variant result for every embryo?

About the embryos:

• How were grades assigned, and do you treat grade differences between euploid embryos as meaningful?
• What is this laboratory’s survival rate through biopsy, freezing, and thaw, in its own data?
• For any “no result” embryo, what are the options, and what would you recommend given how many others I have?

About the plan:

• In what order would you transfer these embryos, and why?
• Would you recommend storing rather than discarding mosaic or no-result embryos?
• What prenatal screening and diagnostic testing would you still recommend if a pregnancy results, and when?
• Is a genetic counseling appointment included, and can my partner or support person attend?

About the bigger picture:

• How does my euploid ratio compare with what you would expect for my age and history?
• If no transferable embryo is available, what would another retrieval realistically add?

Write the answers down or ask whether the consultation can be recorded. Decisions made in the room under emotional pressure are often revisited later, and having the team’s reasoning in your own notes makes that revisiting far easier.

When to call your doctor

Most of the PGT journey happens in a laboratory, but the surrounding IVF treatment involves your body, and certain symptoms need prompt attention regardless of where you are in the results timeline.

After egg retrieval, contact your fertility team the same day if you notice severe or worsening abdominal pain, rapid abdominal swelling or bloating that makes clothing tight, vomiting that prevents you from keeping fluids down, passing very little urine, sudden weight gain over a day or two, or shortness of breath. These can be signs of ovarian hyperstimulation syndrome, a complication of the stimulation medication that Mayo Clinic and NHS guidance describe as uncommon but potentially serious, and it can appear in the week or so after retrieval while you are still waiting for results.

During lining preparation or after a transfer, call if you have heavy vaginal bleeding, fever, severe one-sided pelvic pain, dizziness or fainting, or calf pain and swelling. One-sided pain with a positive pregnancy test needs same-day evaluation to exclude an ectopic pregnancy, which can occur after IVF as it can after natural conception.

Seek emergency care immediately for chest pain, difficulty breathing, coughing up blood, or a leg that is swollen, warm, and painful, because hormonal medication and reduced mobility can raise clot risk.

Call your team on a non-urgent basis if you cannot understand any part of your report, if you receive a result that contradicts what you were told verbally, if you want a second genetic counseling appointment before deciding, or if anxiety or low mood after results is interfering with sleep, work, or relationships. Fertility programs expect these calls, and a request for more time or more explanation is a normal part of care, not an imposition. Every transfer decision remains with you and your treating team.

Frequently asked questions

How to read PGT test results on a typical report?

Look first at the genetic category for each embryo: euploid, aneuploid, mosaic, or no result. Then note any chromosome number attached to aneuploid or mosaic findings, and any percentage for mosaicism. The grade beside it, such as 4AA, describes appearance, not genetics. Ask your team to walk through each line, because thresholds and wording differ between laboratories.

Is 4AA or 5AA better?

They are generally considered comparable. The number describes how expanded the blastocyst is, with 5 meaning hatching has begun; the letters grade the inner cell mass and trophectoderm, and both A grades indicate well-formed cell layers. Embryologists usually weigh the letters more than the number and treat a 4AA and a 5AA as similar in quality.

Can a PGT normal embryo have Down syndrome?

It is very unlikely but not impossible. PGT-A detects trisomy 21 in the sampled cells, so most euploid embryos will not have it. A small false-negative rate, mosaicism confined to untested cells, and rarer translocation forms mean the possibility cannot be fully excluded, which is why prenatal screening is still recommended in pregnancy.

What percentage of embryos are PGT normal?

There is no single figure. The proportion of euploid embryos depends mainly on the age of the person providing the eggs and falls steadily from the early thirties, because chromosome separation in older eggs is more error-prone. Two people of the same age can have very different ratios, so your team’s context for your own results is more useful than an average.

What do PGT-A mosaic embryo results mean for transfer?

A mosaic result means the sampled cells showed a mix of euploid and aneuploid signals. Mosaic embryos can lead to healthy births, so many programs store rather than discard them, but euploid embryos are generally prioritized first. Whether and when a mosaic embryo is transferred depends on the chromosome involved, the type of mosaicism, and a genetic counseling discussion.

What is the difference between a euploid vs aneuploid embryo?

Euploid means the tested cells had the expected number of copies of each chromosome; aneuploid means at least one chromosome was present in the wrong number. Aneuploidy is a major cause of implantation failure and early miscarriage, which is why euploid embryos are usually transferred first. Neither label diagnoses a future child or guarantees an outcome.

Does a euploid result mean I can skip prenatal testing?

No. PGT-A lowers the chance of a chromosomal condition but tests only a few placental cells, has a small error rate, and does not detect single-gene disorders or structural birth differences. Cleveland Clinic and NHS guidance both recommend routine prenatal screening, and diagnostic testing where indicated, in any pregnancy that follows PGT.

What does "no result" on a PGT report mean?

It means the laboratory could not recover enough usable DNA from the biopsy to classify the embryo. It is not a negative finding about the embryo’s chromosomes. Options your team may discuss include re-biopsy after thawing, transferring the embryo untested, or storing it while euploid embryos are used first, depending on your circumstances.

How is a PGT-M report different from a PGT-A report?

PGT-M reports whether each embryo carries a specific gene variant already known in the family, using categories such as affected, unaffected, or carrier depending on the inheritance pattern. PGT-A counts chromosomes. Many people have both run on the same biopsy, and the report then shows a genetic-condition result and a chromosome result side by side for each embryo.

Can embryo biopsy harm the embryo?

Removing a few trophectoderm cells is generally considered low-risk in experienced hands, according to Cleveland Clinic, but a small proportion of embryos do not survive biopsy, freezing, or thawing. Misclassification is another possible harm, since a sample may not represent the whole embryo. Ask your clinic for its own survival data when weighing whether to test.

References

• NHS: IVF
• MedlinePlus Genetics: What are the uses of genetic testing?
• MedlinePlus Genetics: Down syndrome

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.